Bioconjugates and Antibody drug conjugates (ADCs) are revolutionizing cancer therapy with their targeted mechanism of action, offering new hope to cancer patients worldwide. However, bioconjugates are highly complex molecules whose manufacturing presents numerous challenges. Specifically, ADCs are often highly potent entities that necessitate high containment approaches in manufacturing.
Join us for an insightful webinar to learn about best practices and strategies to optimize bioconjugate drug product tech transfers and supplies in clinical or commercial phase. We will explore real-world case studies highlighting:
- Innovative solutions to accelerate clinical tech transfer for bioconjugates drug products and supported by science-driven development approaches
- Tailored approaches from different entry points and either as stand-alone or as part of integrated bioconjugates drug substance/drug product solutions
We also focus on the unique challenges of highly potent biologics manufacturing, discussing the intricacies of high-containment manufacturing that often ADCs require.